A.      Positions and Honors.

1965-1967       Internship & Residency, Int. Med., Vanderbilt Univ. Hosp., Nashville, TN

1967-1968       Residency, Internal Medicine, New York Hospital-Cornell Medical Center, N. Y., N. Y.

1968-1970       Fellowship, Gastroenterology, New York Hospital-Cornell Medical Center, N. Y., N. Y.

1970-1971       Instructor in Medicine, Cornell University Medical College, New York, N.Y.

1968-1971       Guest Investigator, The Rockefeller University, New York, N. Y.

1971-1973       Clinical Investigation Dep't, U.S. Naval Medical Research Unit No.2, Taipei, Taiwan

1973-1979       Assistant Professor, The Rockefeller University.  Assistant Professor of Medicine, Cornell University Medical College. 

1979-1985       Associate Professor and Physician, The Rockefeller University

1979-1987       Adjunct Associate Professor of Medicine and Pharmacology, Cornell Univ. Med. College

1982-1987       Adjunct Attending Physician, Department of Medicine (Gastroenterology), Memorial-Sloan Kettering Cancer Center, New York, N.Y.

1985-1987       Professor, Departments of Medicine and Pharmacology, and Director, Clinical Research Center, New York Medical College,  Valhalla, N.Y. 

1985-1986       Medical Director, The Institute of Clinical Pharmacology, Valhalla, N.Y.

1985-1990       Adjunct Professor and Visiting Physician, The Rockefeller University, New York, N.Y. 

1987-current   Professor, Departments of Preventive Medicine and Community Health, Internal Medicine, and Pharmacology and Toxicology; Associate Director, Division of Human Nutrition (1987-1990);  Director, Division of Human Nutrition (1990-current); Member, Graduate Faculty; Associate Program Director, General Clinical Research Center (1993-current, Acting Director 2002); Director, Clinical Research Education Office (1998-current), The University of Texas Medical Branch, Galveston, Texas.

Honors and Awards:

1964                Goldberger Summer Fellowship in Nutrition, The American Medical Association.

1977                Research Career Development Award, 1 K04 GM00330 from the National Institutes of Health

 

B.        Selected peer-reviewed publications (from total of 95).

1.      Anderson KE, Conney AH, Kappas A. Nutrition and oxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate and protein. Clinical Pharmacology and Therapeutics 1979;26:493-501.

2.      Anderson KE, Freddara U, Kappas A. Induction of hepatic cytochrome P-450 by natural steroids:  Relationships to the induction of d-aminolevulinate synthase and porphyrin accumulation in the avian embryo. Arch Biochem Biophys 1982;217:597-608.

3.      Anderson KE, Simionatto CS, Drummond GS, Kappas A. Pharmacokinetics of Sn-protoporphyrin and suppression of hyperbilirubinemia in humans. Clin Pharmacol Ther 1986;39:510-521.

4.      Anderson KE, Goeger DE, Carson RW, Lee S-MK, Stead RB. Erythropoietin for treatment of porphyria cutanea tarda in a patient on long-term hemodialysis.  New Engl J Med 1990; 322:315-317 .

5.      Anderson KE, Spitz IM, Bardin CW, Kappas A. A GnRH analogue prevents cyclical attacks of porphyria. Arch Int Med 1990;150:1469-1474.

6.      Anderson KE, McCleery RB, Vesell ES, Vickers FF, Kappas A.  Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology 1991; 13:941-946. 

7.      Anderson KE, Kappas A.  Dietary regulation of cytochrome P450. Ann Rev Nutr 1991;11:141-167.

8.      Chen C-H, Astrin KH, Lee G, Anderson KE, Desnick RJ.  Mutations in the hydroxymethylbilane synthase gene: an initiation codon missense mutation in the housekeeping transcript causes "variant acute intermittent porphyria" with normal expression of the erythroid-specific enzyme. J Clin Invest 1994; 94:1927-37. 

9.      Egger NG, Goeger DE, Anderson KE. Effects of chloroquine in hematoporphyrin-treated animals. Chemico-Biological Interactions 1996;102:69-78. 

10.  Egger NG, Schoenecker JA Jr, Gourley WK, Motamedi M, Anderson KE, Weinman SA. Photosensitization of experimental hepatocellular carcinoma after δ-aminolevulinic acid. J Hepatol 1997;26:913-920. 

11.   Sinclair PR, Gorman N, Shedlofsky SI, Honsinger C, Sinclair JF, Karagas MR, Anderson KE. Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med 1997;130:197-201.

12.  Goeger DE, Anderson KE, Hsie AW. Coumarin chemoprevention against aflatoxin B₁ induced gene mutation in a mammalian cell system: a species difference in mutagen activation and protection with chick embryo and rat liver S9. Environmental and Molecular Mutagenesis 1998:32:64-74.

13.   Goeger DE, Hsie AW, Anderson KE. Co-mutagenicity of coumarin (1,2-benzopyrone) with aflatoxin B₁ and human liver S9 in mammalian cells. Food and Chemical Toxicology, 37:581-589, 1999. 

14.   Lu L-J, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. Increased urinary excretion of 2-hydroxyestrone but not 16α-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Research, 60:1299-1305, 2000. 

15.   Wan XS, Lu LJ, Anderson KE, Ware JH, Kennedy AR. Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by monoclonal antibody-based immunoassay. Cancer Epidemiol Biomarkers & Prevention 2000; 9:741-747. 

16.   Ramdall RB, Cunha L, Astrin KH, Katz DR, Anderson KE, Glucksman M, Bottomley SS, Desnick RJ: Acute intermittent porphyria: novel missense mutations in the human hydroxymethylbilane synthase gene. Genetics in Medicine 2000;2:290-5.

17.   Barone GW, Gurley BJ, Anderson KE, Ketel BL, Abul-Ezz SR. The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. J Clin Pharm 2000;41:113-5. 

18.   Anderson KE, Sassa S, Bishop D, Desnick RJ. Disorders of heme biosynthesis: X-Linked sideroblastic anemia and the porphyrias.  In: Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B, Childs B, eds. The Metabolic and Molecular Basis of Inherited Disease, 8th edition. New York: McGraw-Hill, 2000: 2991-3062.

19.   Frank J, Jugert FK, Merk HF, Kalka K, Goerz G, Anderson K, Bickers DR, Poh-Fitzpatrick MB, Christiano AM: A spectrum of novel mutations in the protoporphyrinogen oxidase gene in 13 families with variegate porphyria. J Invest Dermatol 2001;116:821-3.

20.   Egger NE, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C and inherited uroporphyrinogen decarboxylase deficiency. Digestive Diseases and Sciences 2002; 47:419-426.

21.   Poh-Fitzpatrick MB, Wang X, Anderson KE, Bloomer JE, Bolwell B, Lichtin AE: Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Derm 2002;46:861-866.

22.   Anderson, KE. The porphyrias (Chapter 223). In: L. Goldman and D. Ausiello., eds  Cecil Textbook of Medicine. Philadelphia, W.B. Saunders Co., 2004: 1292-1300.

23.   Anderson, KE, Bloomer, JE, Bonkovsky, HL, Kushner, JP, Pierach, CA, Pimstone, NR and Desnick, RJ.  Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Int Med, 2005;142:439-50.

24.   Huang Y, Cao S, Nagamani M, Anderson KE, Grady J, Lu L-JW: Decreased circulating levels of tumor necrosis factor-alpha (TNF-a) in postmenopausal women during consumption of soy containing isoflavones. J Clin Endocrinol Metab. 2005;90:3956-62. 

25.   Nhan S, Anderson KE, Nagamani M, Grady JJ, Lu LJ: Effect of a soymilk supplement containing isoflavones on urinary f2 isoprostane levels in premenopausal women. Nutrition and Cancer 2005;53:73-81.

26.   Akagi R, Kato N, Inoue R, Anderson KE, Jaffe EK, Sassa S: delta-Aminolevulinate dehydratase (ALAD) porphyria: The first case in North America with two novel ALAD mutations. Molec Genet Metab. Online 12/9/05.

27.   Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, Phillips JD, Sassa S. Dual gene defects involving d-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient.  Br J Haematol. 2006;132:237-243.

 

C.  Research Support.

 

Ongoing Research Support:

 

1.  5 K30 HL04126                  (PI: Anderson, Karl E.)                                                06/01/99 – 05/31/10

NIH – National Heart, Lung and Blood Institute

"Clinical Research Education Office at UTMB"

Support of clinical research education.

 

2.  5 M01 RR000073         (Associate Program Director; PI: Paresi, Valerie)            12/1/63-12/31/10

     NIH-National Center for Research Resources     

     "General Clinical Research Center"

Support of clinical research.

 

3.  (PI: Anderson, Karl E.)                                                                                           01/01/97-08/31/06

American Porphyria Foundation

"Telemedicine and Porphyria"

A pilot project to assess the efficacy of telemedicine for evaluating and advising patients with a rare disease at a distance using video teleconferencing and other methods.  The results may be applicable to other rare diseases for which expertise exists at only a few locations in the U.S. 

 

4.  (PI: Anderson, Karl E.)                                                                                                 08/01/00-08/31/06

     American Porphyria Foundation                                             

"Drug Safety in Acute Porphyria"

An observational study in porphyria patients to record experience with drugs to treat other concomitant conditions for which there is currently little information as to safety in acute porphyrias. 

 

5.  NIH 1RO1CA95545-01A1  (Co-investigator; PI; Lu)                                                    09/15/03 - 08/31/07

“Mammographic Density and Soy Isoflavones”                     

To study the effect of supplementation with isoflavones and placebo on mammographic density in premenopausal women.

 

6.  DAMD17-01-1-0417     (Co-investigator; PI: Lu)                                                                08/1/01-7/31/07    

US Army Medical Research and Materiel Command                   

"Soybean Diet and Breast Density"

To determine if three years of isoflavone-free soya consumption by women will reduce mammographic density and ovarian steroid hormone levels when compared to a control group.

 

7.                     (PI:  Anderson, Karl E.)                                                                 04/23/03-4/22/06

Zymenex (formerly HemeBiotech) A/S                                                     

"A multicentre, double-blind, randomized, placebo-controlled, parallel group trial investigating the efficacy and safety to Porphozym™ (recombinant human porphobilinogen deaminase) in the treatment of acute attacks in AIP"

A trial of enzyme replacement for treatment of acute attacks of acute intermittent porphyria.

 

8. FD-R-02604            (PI: Anderson, Karl E.)                                                            9/30/05 – 9/29/08

USPHS-FDA Orphan Drug Program                                            

“Hydroxychloroquine vs. Phlebotomy for Porphyria Cutanea Tarda”

A study comparing efficacy and safety of two standard treatments for porphyria cutanea tarda, and the influence of susceptibility factors in treatment response.

 

 

Completed Research Support: 

 

1.  FD-R-001459               (PI: Anderson, Karl)                                                          08/01/97 - 6/01/03

USPHS-FDA Orphan Drug Program

“Tin Mesoporphyrin and Heme Therapy in Acute Porphyria”

Studies of tin mesoporphyrin to enhance the effects of heme therapy in patients with acute porphyrias, including dose-ranging, acute treatment and prevention protocols. 

 

2.                     (PI:  Lau, Daryl T.-Y.)                                                                          04/1/04-7/31/04    

Gastrointestinal Research Interdisciplinary Program (GRIP) Seed Grant                       

"Liver Gene Expression in HCV-Associated Porphyria Cutanea Tarda"

A pilot study of gene expression in liver in patients with porphyria cutanea tarda and hepatitis C, using Affimetrix gene chips. 

 

3.   (PI:  Abdel-Rahman, S.)                                                                                        07/1/02-6/30/05

Doris Duke Charitable Foundation (Innovation in Clinical Research Award)

"CYP2C9 Genotype and Long Term Warfarin Dose Requirements"

To define the role of a genetic polymorphism for the enzyme that metabolizes warfarin in determining dose requirements for this drug in patients who are followed for long term anticoagulation in the Anticoagulation Clinic at UTMB.

 

4.  5R01AA12852        (Co-investigator; PI:  Shedlovsky)                                          09/30/01-8/31/05

USPHS-NIH   Subcontract – University of Kentucky                     

"Hepatic Cytochromes P450 in Hepatitis C Oxidative Injury"

Studies of cytochrome P450 in patients with hepatitis C, including some with associated porphyria cutanea tarda, to determine if activities of specific isoforms of P450, such as CYP1A2, CYP2E1 and CYP3A4, are increased in these disorders.  These will be studied using noninvasive drug probes.  Effects of interferon, phlebotomy, ethanol exposure and high fat diets will be observed.  These clinical studies will utilize the GCRCs at the University of Kentucky and the University of Texas Medical Branch.

 

5.                                 (Co-investigator; PI:  Lu)                                                                 01/1/02-12/30/05

American Institute for Cancer Research                                

"Comparative Hormonal Effects of Diets Containing Soy and Animal Protein"

To test further the hypothesis that there are dietary determinants for influencing ovarian hormones of premenopausal women as observed in prior studies.

 

6. 1RO1GM64797       (Co-investigator; PI:  Putscha, L.)                                          08/10/02-11/30/05

USPHS-NIH (funding to UTMB through Wyle Laboratories)

"Bioavailability and Pharmacodynamics of Promethazine in Human Subjects"

A NASA study of the pharmacokinetics and pharmacodynamics of the drug most commonly used for motion sickness during space flight, as affected by route of administration and head-down bedrest.